Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.
Why Kymera Therapeutics Stock Crushed it This Week
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech sector.
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Andy Chen - Wolfe Research Paul Jeng - Guggenheim Ron Feiner - JPMorgan Jeff Jones - Oppenheimer Brad Canino - Stifel Marc Frahm - TD Cowen Ellie Merle - UBS Securities Parth Patel - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Fortea-Verdejo - Wells Fargo Eric Wong - Goldman Sachs Jeet Mukherjee - BTIG Sudan Loganathan - Stephens Operator Good day everyone. My name is Megan and I will be your conference operator today.
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.25 per share a year ago.
Kymera Provides Pipeline Objectives for 2025, Stock Gains
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kymera: Protein Degradation Could Drive Dupixent-Like Value
Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for immuno-inflammatory disorders, shows promise with Phase 1 data expected in the first half of 2025. The company has $911 million in cash, sufficient to fund operations into mid-2027, covering key milestones and pipeline developments.
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel Enyindah-Asonye - Morgan Stanley Kelly Shi - Jefferies Jeff Jones - Oppenheimer Eric Joseph - J.P.
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.
